Espislogen, a London, UK-based company which specializes in the development of immunoglobulin E (IgE) antibodies to treat cancer, raised £12.5M in Series B funding.
The round, which brought the total amount to £43.25M, included participation from British Patient Capital, Novartis Venture Fund, Epidarex Capital, 3B Future Health Fund and ALSA Ventures.
The company intends to use the funds to expand operations ann its R&D sector.
Led by CEO Tim Wilson, Epsilogen advances immunoglobulin E (IgE) antibodies to treat cancer. Its natural function is to provide immunological defence against certain parasites. This functionality makes it an ideal treatment of solid tumours due to its potency, enhanced tumour access and long tissue half-life.
Epsilogen’s lead product candidate, MOv18 IgE, is the first therapeutic IgE antibody to enter the clinic and encouraging data from a completed Phase I trial demonstrated MOv18 IgE to be safe and well tolerated with early signs of clinical activity. Epsilogen has recently completed large scale GMP manufacture of MOv18 IgE (the first time this has been achieved for an IgE antibody) and will initiate a Phase Ib trial in platinum-resistant ovarian cancer patients later this year. The company is also developing a pipeline of IgE therapies in oncology as well as proprietary platforms including IgE bispecifics and unique IgE/IgG combination antibody molecules (IgEGs) with enhanced functionality.
Epsilogen began operations in 2017 as a spin-out of King’s College London and has attracted venture capital financing from Epidarex Capital, Novartis Venture Fund, 3B Future Health, British Patient Capital, ALSA Ventures and Schroders Capital amongst others.
FinSMEs
09/09/2024